Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib
Background Although in metastatic renal cell carcinoma (mRCC) patients with intermediate
and poor risk the benefit of combination strategies versus tyrosine kinase inhibitor (TKI) has …
and poor risk the benefit of combination strategies versus tyrosine kinase inhibitor (TKI) has …
[HTML][HTML] Prognostic significance of pseudocapsule status in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
W Xi, Y Hou, X Hu, Y Xia, S Jiang, H Wang… - Translational …, 2021 - ncbi.nlm.nih.gov
Background We sought to determine whether pseudocapsule (PS) features have prognostic
implications in patients with metastatic renal cell carcinoma (mRCC). Methods We …
implications in patients with metastatic renal cell carcinoma (mRCC). Methods We …
[HTML][HTML] Real-world data on the efficacy and safety of pazopanib in IMDC favorable-and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective …
A Anwaier, J Chen, H Zhou, X Zhao… - Translational …, 2022 - ncbi.nlm.nih.gov
Background Pazopanib was recommended as first-line treatment option for Metastatic renal
cell carcinoma (mRCC), while evidence from strictly selected patients has poor external …
cell carcinoma (mRCC), while evidence from strictly selected patients has poor external …